LSE · DXRX.L
Diaceutics PLC
£2.04£0.00 (0.0%)
Diaceutics PLC’s quoted price sits in the upper half of its reported 52-week range, 3.1% below the high.
Loading market information…
LSE · 4BB.L · GBp
Stock price, earnings
Quote as of Oct 29, 2026, 09:13 AM UTC. Cached market data; not a live quote.
One-year closing-price history · GBp. Historical prices are not a forecast.
4basebio PLC’s quoted price sits in the lower half of its reported 52-week range, 35.37% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
4basebio PLC’s next earnings report is currently expected on Jun 2, 2027, with estimated earnings per share of -£0.60. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow 4basebio PLC’s reporting calendar.
THE COMPANY BEHIND THE TICKER
4basebio PLC, an enterprise established in 2020 and situated in Cambridge, United Kingdom, is dedicated to the entire process, from conception to delivery, of synthetic DNA and RNA products. The company also provides advanced non-viral vector solutions, with operations spanning the United States, Europe, and other international markets. Their comprehensive offerings encompass research kits, bulk enzymes, various other biological products, as well as crucial licensing and AVV manufacturing services. The company primarily caters to clients within the biotech, pharmaceutical, and contract development and manufacturing organization (CDMO) industries. Notably, the firm adopted its current name, 4basebio PLC, in July 2021, having previously been known as 4basebio UK Societas.
Latest available per-share figures in GBP. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:17 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| £238.00K0.0% vs estimate |
| Q1 2023 | May 11, 2023 | -£0.22 | £116.00K |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
£2.04£0.00 (0.0%)
Diaceutics PLC’s quoted price sits in the upper half of its reported 52-week range, 3.1% below the high.
£0.89£0.00 (0.0%)
Scancell Holdings plc’s quoted price sits in the lower half of its reported 52-week range, 69.83% below the high.
£20.25-£0.25 (-1.22%)
Bioventix PLC’s quoted price sits in the upper half of its reported 52-week range, 10.2% below the high.
£0.24+£0.00 (+1.93%)
EKF Diagnostics Holdings plc’s quoted price sits in the lower half of its reported 52-week range, 18.1% below the high.
£0.10+£0.00 (+2.63%)
Ondine Biomedical Inc.’s quoted price sits in the upper half of its reported 52-week range, 37.1% below the high.
£6.80+£0.07 (+1.04%)
Hemogenyx Pharmaceuticals Plc’s quoted price sits in the lower half of its reported 52-week range, 44.26% below the high.
£0.04+£0.00 (+6.12%)
ImmuPharma PLC’s quoted price sits in the lower half of its reported 52-week range, 67.09% below the high.
£0.15-£0.01 (-7.58%)
Sareum Holdings plc’s quoted price sits in the lower half of its reported 52-week range, 61.88% below the high.
